Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.59    -0.31 (-10.69%)
Bid:
2.60
Ask:
2.91
Spread: 0.31 (11.923%)
Market Cap: £4.73m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

Contract extension signed

25 Jan 2019 07:00

RNS Number : 0694O
Nanoco Group PLC
25 January 2019
 

25 January 2019

 

NANOCO GROUP PLC

("Nanoco" or the "Group")

 

Contract extension signed

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from our technology platform, today announces that it has signed a contract extension to deliver additional services and materials to an undisclosed US Company (the 'US Company').

In February 2018, Nanoco announced the signing of a Material Development and Supply Agreement with the US Company. Since then, Nanoco has successfully completed a number of technical milestones as well as substantially completing the expansion of the Runcorn facility. Following on from the progress to date, the US Company has now extended the scope of work required from Nanoco.

The contract extension runs from January 2019 to December 2019. During that period, Nanoco will carry out stress testing and process optimization on the new production facility. The majority of revenue is expected to be earned during the period of the agreement, with limited deferrals, and with no contingent or milestone based payments.

 

The Group noted in its Preliminary Results announcement, on 16 October 2018, that revenue was expected to double in the financial year ending 31 July 2019. At that time, approximately £3.0m of revenue was noted as being under contract, with further potential agreements under active discussion. Successful delivery of the services under the contract extension noted above will fully underpin those revenue expectations and also add a similar sum to the backlog of future revenue expected in FY20. The contract extension also underpins the Board's current expectations for operating results and cash flows. The Group remains in active discussion on additional potential commercial agreements with a number of parties that could create upside to these expectations.

 

Michael Edelman, Chief Executive of Nanoco, said:

 

"We are pleased to announce today's contract extension with our US Customer. This extension is a clear demonstration of Nanoco's unique capabilities and value proposition with respect to designing and producing complex nano-materials.

 

"We are proud to be innovators in the development of quantum dots and other nano-materials, always improving their quality and performance, with extensive intellectual property and specialist knowledge that gives us a clear competitive lead in this technology. We look forward to further strengthening and deepening the relationship with the US Customer."

 

This announcement contains inside information as defined in EU Regulation No. 596/2014 and is in accordance with the Group's obligations under Article 17 of that Regulation.

 

The person responsible for arranging the release of this announcement on behalf of the Group is Brian Tenner, Chief Operating Officer and Chief Financial Officer.

 

For further information, please contact:

Nanoco Group PLC:

Michael Edelman, CEO +44 (0) 161 603 7900

Brian Tenner, COO & CFO +44 (0) 161 603 7900

Caroline Watson, Investor Relations Manager +44 (0) 7788 897 357

cwatson@nanocotechnologies.com

 

MHP Communications: +44 (0) 20 3128 8570

Reg Hoare / Giles Robinson / Pete Lambie

nanoco@mhpc.com

 

Notes for editors:

 

About Nanoco Group plcNanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display and Electronics markets. One of the interesting properties of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco has non-exclusive manufacturing and marketing licensing agreements in display with The Dow Chemical Company, Merck KGaA of Germany and Wah Hong Industrial Corporation of Taiwan.

Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CNTUSORRKAAAUUR
Date   Source Headline
5th Jun 202611:55 amRNSTR-1: Notification of major holdings
27th May 20267:00 amRNSIntention to delist from London Stock Exchange
20th Apr 20265:37 pmRNSDirector/PDMR Shareholding
20th Apr 20267:00 amRNSInterim Results
13th Apr 20267:00 amRNSNotice of Results
26th Mar 20267:00 amRNSShoei Litigation Conclusion
19th Mar 20267:00 amRNSStay of Shoei Litigation
23rd Feb 20267:00 amRNSShoei Litigation Update
26th Jan 20267:00 amRNSConclusion of CDX process & Directorate changes
15th Jan 20261:08 pmRNSReceipt of Litigation Proceeds
13th Jan 20264:50 pmRNSResult of AGM
12th Jan 20267:00 amRNSLitigation update
9th Dec 20257:00 amRNSBlocklisting Six-Monthly Return
8th Dec 202511:16 amRNSNotice of AGM
27th Nov 20257:00 amRNSResponse to non-infringement claim
26th Nov 20257:00 amRNSAnnual Report and Accounts
20th Nov 20257:00 amRNSLitigation outcome – Settlement agreed
18th Nov 20257:07 amRNSPreliminary Results
13th Nov 20257:00 amRNSNotice of Results
4th Nov 20257:06 amRNSExtension of Joint Development Agreement
15th Oct 20257:00 amRNS-RAwarding of Government Grant
30th Sep 20254:30 pmRNSTotal Voting Rights and Share Capital
8th Sep 20257:00 amRNSIssue of Equity and Director/PDMR Shareholdings
19th Aug 20257:00 amRNSFull Year Trading Update & Director Retirement
9th Jun 20257:00 amRNSBLOCKLISTING SIX-MONTHLY RETURN
28th Apr 202510:48 amRNSJoint Development Agreement
25th Apr 20257:00 amRNSPatent infringement lawsuit against LG
17th Apr 20253:54 pmRNSHigh Court Confirmation of Capital Reduction
15th Apr 20257:00 amRNSInterim Results & Investor Presentation
13th Mar 20257:00 amRNSNotice of Results
21st Jan 20252:20 pmRNSAnnual General Meeting – Voting Results
18th Dec 20248:26 amRNSDirector/PDMR Shareholding
13th Dec 20241:23 pmRNSResult of General Meeting
9th Dec 20247:00 amRNSBlock Listing Six Monthly Return
6th Dec 20246:30 pmRNSNotice of AGM
29th Nov 20247:00 amRNSGlass Lewis and ISS recommendations
28th Nov 20243:23 pmRNSDirector/PDMR Shareholding
28th Nov 20241:25 pmRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNS2024 Annual Report
20th Nov 20247:00 amRNSPreliminary Results
15th Nov 202411:00 amRNSPosting of Circular and Notice of General Meeting
30th Oct 20247:01 amRNSCompletion of Buyback Programme
30th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Oct 20247:00 amRNSReceipt of General Meeting Requisition Notice
23rd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Oct 20247:00 amRNSAppointment of CEO and Notice of Results
22nd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
21st Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
18th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.